GILEAD SCIENCES, INC.
Long book
$2.12B
Q1 2026
Positions
6
Top-10 weight
100%
concentration
Last quarter
+21.0%
SPY +14.8%
Turnover
0%
of book per quarter
Strategy in plain words
auto-generated from filingsGILEAD SCIENCES, INC. is a concentrated fundamental stock-picker, specialised in healthcare (100% of the long book), running a $2.12B US long book across 6 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. The book barely moves quarter to quarter — a patient, low-turnover holder. Current anchor positions: ARCELLX INC, ARCUS BIOSCIENCES INC, LAKEFRONT BIOTHERAPEUTIC-ADR, ASSEMBLY BIOSCIENCES INC, KYVERNA THERAPEUTICS INC.
Over the last 6 quarters its long book ran on average 6.2pp per quarter ahead of the S&P 500, beating the index in 4 of 6 quarters. We rate its filings highest-signal: new buys here are worth attention.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q4 2024
-29.8%
Q1 2025
+13.3%
Q2 2025
+40.9%
Q3 2025
+29.2%
Q4 2025
-9.9%
Q1 2026
+21.0%
Sector allocation
Healthcare 52%
Other 48%
Long book by quarter
What does GILEAD SCIENCES, own?
Q1 2026 13F13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 8, 2026 | 6 | $2.12B | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 12, 2026 | 6 | $1.94B | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 13, 2025 | 9 | $1.79B | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 14, 2025 | 14 | $1.28B | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 13, 2025 | 14 | $1.18B | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 13, 2025 | 16 | $1.55B | canonical | SEC ↗ |